메쥬 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 주영일, was filed 10 Apr 2026.
메쥬: what insiders have been doing
메쥬, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). In the past year (2 November 2025 to 2 November 2026), 9 filings came from 7 insiders.
No insider sold shares on the market over the period. Instead, the filings list 8 purchases totalling €135k, made by 7 insiders. No amount is published for 7 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €135k, the purchase published on 10 April 2026 by 주영일 is the largest of the period. The buyers include 3 senior executives, 1 finance chief and 1 chief executive.
Compared with its exchange (2,655 companies, median 7 filings), a count of 9 filings is above the norm. The full history, which starts in 2026, counts 8 purchases against no sales.
The clock since the last published purchase (10 April 2026) now reads 214 days. The median gap between a trade and its publication by DART (FSS) is 6 days. This delay matters because a trade only becomes useful information once it is public.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySale+1 other insider
Since the insiders bought
- -45.5%Entry ₩28,750 · Close 30 Oct 2026 ₩15,660
- -52.4%Entry ₩32,900 · Close 30 Oct 2026 ₩15,660
- -57.7%Entry ₩37,000 · Close 30 Oct 2026 ₩15,660
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 80,000 shares@ ₩2,941.00100.0% of flowShareKRXDART:20260410003438Canonical exit: 2 Jul 2026 (T+90)
- 0KRXDART:20260410003534
- 507,071 sharesKRXDART:20260402003796Canonical exit: 24 Jun 2026 (T+90)
- 331,674 sharesKRXDART:20260401003992Canonical exit: 24 Jun 2026 (T+90)
- 200,000 sharesShareKRXDART:20260401002065Canonical exit: 24 Jun 2026 (T+90)
- 822,380 sharesShareKRXDART:20260401002004Canonical exit: 24 Jun 2026 (T+90)
- 2,751,560 sharesShareKRXDART:20260401001870Canonical exit: 24 Jun 2026 (T+90)
- 3,973,940 sharesKRXDART:20260401002211Canonical exit: 24 Jun 2026 (T+90)
- 80,000 sharesShareKRXDART:20260401002103Canonical exit: 24 Jun 2026 (T+90)
9 of 9 declarations
About 메쥬
메쥬 is a healthcare and pharmaceutical company listed on the XKRX. It specializes in the development and commercialization of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
